RECRUITING Not applicable ClinicalTrials.gov

Post-immunotherapy Nephrectomy for Metastatic Kidney Cancer After Complete or Major Response to Systemic Therapy

Sponsor: Institut Paoli-Calmettes • ClinicalTrials.gov ID: NCT06882486

Registry updated: 2026-10-14

Recruiting for Similar Conditions?

Sponsors are looking for patients like you. See if you qualify for compensated research studies.

Description

In the current era of immune checkpoint inhibitors (ICI), the role and timing of nephrectomy remains unknown, particularly in cases of residual kidney disease after a major response at metastatic sites. In these cases, the rationale for a delayed nephrectomy is that it might achieve a long-term response. This strategy could allow some patients to discontinue treatment and maintain tumor response. Furthermore, this approach might provide a potentially curative option for patients with metastases that are managed with and responding to ICI. Regarding the results of our first retrospective cohort data (showing that two thirds of patients are free from recurrence without systemic treatment after nephrectomy), we designed a non-comparative randomized phase II trial assessing progression-free survival of patients with complete response or major partial response after ICI-based treatment, operated on delayed nephrectomy with discontinuation of systemic therapy (experimental arm) and in patients managed with continuation of systemic therapy without nephrectomy (control arm). In a de-escalation approach, this strategy may have sense to allow patients with an excellent response to immunotherapy to stop systemic treatment with a curative objective and a substantial impact from a medico-economic point of view.

Interventions

nephrectomy (Procedure)
Nephrectomy scheduled within 3 months of inclusion. Patients may continue their systemic treatment at the usual rate until D-5 prior to surgery. Treatment will not be resumed after surgery. Surgery may consist of partial or enlarged nephrectomy, with or without associated lymph node dissection, depending on technical possibilities and at the surgeon's discretion.

Eligibility criteria

Inclusion Criteria: 1. Patient aged ≥ 18 years 2. Diagnosed with synchronous metastatic kidney cancer 3. With primary tumor still in place (no primary cytoreductive nephrectomy) 4. Having received systemic ICI immunotherapy-based combination therapy 5. In CR or mPR (defined as \>75% response in metastatic lesions from baseline) according to the Response Evaluation Criteria in Solid Tumors (RECIST, version 1.1), excluding the primary renal lesion. 6. Signed consent to participate 7. Affiliated to the national social security scheme or beneficiaries of such a scheme Exclusion Criteria: 1. Women who are or may become pregnant (without effective contraception) or who are breast-feeding. 2. Person in an emergency situation or unable to give consent. 3. An adult under legal protection (guardianship, curators or safeguard of justice), 4. Inability to undergo medical follow-up for geographical, social or psychological reasons. 5. Patients who have undergone prior cytoreductive nephrectomy 6. Patients considering nephrectomy for symptomatic disease, but without major response (CR or mPR) in metastatic disease 7. Patients with non-metastatic disease at diagnosis who have received ICI in a neo-adjuvant setting 8. Patients with contraindications to surgery or ineligible for nephrectomy 9. Patients not wishing to undergo nephrectomy 10. Patients with end-stage renal disease

Conditions

Kidney Cancer

Locations

Institut Paoli-Calmettes — Marseille, Institut Paoli-calmettes, France

Partner with Nurenyx

Showcase your study to thousands of motivated patients matching your criteria.

Learn More

Official Source

Data sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

View Official Record

Accelerate Your Clinical Trial Recruitment